14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CGEN vs SLN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas SLN carries 45.2/100 (HOLD) at $19.80 (N/M Forward P/E, -11905.9% operating margin).
Growth vs. Quality Trade-Off: CGEN earns the overall head-to-head edge with a stronger Unified Composite Score (47.1/100 HOLD vs. SLN 45.2/100 HOLD) and 1.44β · 62% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEN vs SLN. Trailing 12-month operating profitability (CGEN 41.3% vs SLN -11905.9%) and valuation multiples (CGEN 12.4x vs SLN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.2B market capitalization and -11905.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CGEN vs SLN Key Questions & Quantitative Answers
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas SLN carries 45.2/100 (HOLD) at $19.80 (N/M Forward P/E, -11905.9% operating margin). Growth vs. Quality Trade-Off: CGEN earns the overall head-to-head edge with a stronger Unified Composite Score (47.1/100 HOLD vs. SLN 45.2/100 HOLD) and 1.44β · 62% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SLN leads the Growth & Scale pillar: CGEN posts +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin), compared with SLN at +197.2% YoY revenue growth and +0.0% YoY earnings growth on $456,000 TTM revenue (95.0% gross margin, -11905.9% operating margin). On trailing 12-month operating scale, CGEN generates $76M in USD-normalized revenue versus $456,000 for SLN. In operating R&D and SG&A reinvestment, CGEN deploys 44.9% of Rev ($34M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLN.
CGEN screens cheaper on headline valuation multiples. CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin), whereas SLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEN (57.2% ROE) versus SLN (-35.6% ROE) capital efficiency.
In options market volatility and institutional positioning, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk). By comparison, SLN carries 55.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.92β · 4% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.